Wellington Partners
VC Fund
Munich, Germany
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
- Total investments:
- 201
- Last investment:
- Lead investor:
- 30%
- Fund size:
- $222M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Wellington Partners invests in
Stages Wellington Partners invests in
Countries Wellington Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.1M–$36M
- Series B
- $8.3M–$60M
Investment Focus
Industry
- Health Care 37 (18%)
- Biotechnology 30 (15%)
- Medical 26 (13%)
- Software 16 (8%)
- Therapeutics 16 (8%)
Stage
- Series A 51 (25%)
- Series B 44 (22%)
- Funding Round 22 (11%)
- Series C 21 (10%)
- Seed 15 (7%)
Country
- Germany 38 (19%)
- United States 20 (10%)
- United Kingdom 12 (6%)
- France 9 (4%)
- Switzerland 9 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Erich Schlick
General Partner
|
General Partner | Total investments: 9 | Find email | |
Rolf Christof Dienst
General Partner and Founder Emeritus
|
General Partner and Founder Emeritus | Total investments: 12 | Find email | |
Anja Weibel
Finance Manager
|
Finance Manager | Total investments: 0 | Find email | |
Frank Boehnke
General Partner
|
General Partner | Total investments: 8 | Find email | |
Harald Keller
Partner
|
Partner | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Beren Therapeutics
|
Beren Therapeutics is a biotechnology company that develops innovative therapies to make them accessible to every patient. The company was founded in 2020 and is based in Thousand Oaks, CA. | $135M / Venture - Series Unknown / Jun 10, 2026 | |
Nuclidium
|
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $33.6M / Series B / May 28, 2026 | |
nyra health
|
nyra health is an artificial intelligence and evidence-based neurological research tablet app that offers a revolutionary form of therapy. nyra health was founded in 2020 and was headquartered in Vienna, Austria. | $23.6M / Series A / Feb 24, 2026 | |
SNIPR Biome
|
SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases. The company uses CRISPR technology that can subvert elements of the endogenous bacterial CRISPR machinery to eliminate hazardous bacteria in vivo, providing the health professionals with medicines that selectively target andkill bacteria with specific DNA sequences. | $40.9M / Series B / Aug 07, 2025 | |
|
Nuclidium
|
NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $131.8M / Series B / Jul 10, 2025 | |
Hilo
|
Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com. | $42M / Series B / May 01, 2025 | |
HepaRegeniX
|
HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a keyregulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis. | $24.3M / Venture - Series Unknown / Apr 15, 2025 | |
|
HepaRegeniX
|
HepaRegeniX is developing drugs for treating acute and chronic liver diseases that effectively restore the regenerative capacity of hepatocytes. The therapeutic concept is founded on research by Professor Lars Zender’s group at the University Hospital Tübingen, which identified mitogen-activated protein (MAP) kinase kinase 4 (MKK4) as a keyregulator of liver regeneration. Work by Professor Zender’s team showed that using small RNA molecules to suppress MKK4 gene expression restored the regenerative capacity of hepatocytes, even in severely diseased livers. Founded in 2015, HepaRegeniX is developing small-molecule MKK4 inhibitors to treat liver disorders, potentially including nonalcoholic steatohepatitis. | $24.3M / Venture - Series Unknown / Apr 15, 2025 | |
Aignostics
|
Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis. | $34M / Series B / Oct 29, 2024 | |
CorFlow Therapeutics
|
CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients. | $48.5M / Series B / Sep 10, 2024 | |
| See all 201 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Wellington Partners invest in?
Wellington Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 201 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Wellington Partners's check size?
Wellington Partners typically joins rounds of $3.1M–$36M at Series A and $8.3M–$60M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Wellington Partners participates in.
How do I contact Wellington Partners?
Public channels for Wellington Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wellington Partners?
The team at Wellington Partners includes Erich Schlick (General Partner), Rolf Christof Dienst (General Partner and Founder Emeritus) and Anja Weibel (Finance Manager), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
